DavidE.GellerMD

Cystic Fibrosis Pulmonology

VP of Pulmonary and Rare Diseases at Arcturus Therapeutics

Dr. Geller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Arizona College of Medicine-TucsonFellowship, Pulmonary Disease and Critical Care Medicine, 1983 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1980 - 1983
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1980

PubMed

54 citations
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT...
Patrick A. Flume, Donald R. VanDevanter, Elizabeth E. Morgan, Michael N. Dudley, Jeffery Loutit
Journal of Cystic Fibrosis. 2016-07-01
27 citations
Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
Alfred Haynes, David E. Geller, Jeffry G. Weers, Brian Ament, Richard Pavkov
Pediatric Pulmonology. 2016-04-01
11 citations
Tiotropium Respimat® in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials
Felix Ratjen, Paul Koker, David E. Geller, Berengere Langellier-Cocteaux, Florence Le Maulf
Journal of Cystic Fibrosis. 2015-09-01

VP Pulmonary & Rare Diseases, Arcturus TherapeuticsHead of clinical development for mRNA-based medicines for cystic fibrosis and ornithine transcarbamylase deficiency.2020 - 2024
Medical Director, AbbVie, IncMedical lead for cystic fibrosis CFTR modulator programDisclosure: Employee2014 - 2020